|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Akronym/Firma** | **Substanz** | **Phase** | **Indikation** | **Beschreibung** | **Rekrutierung** |
| **IPF und PF-ILD STUDIEN** | | | | | |
| ZEPHYRUS/  Fibrogen | Pamrevlumab (FGCL-3019-095) | III | Idiopathische Lungenfibrose | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab  in Subjects with Idiopathic Pulmonary Fibrosis (IPF). | Abgeschlossen |
| CSL312\_2002/  CSL Behring | CSL312\_2002 | IIa | Idiopathische Lungenfibrose | A randomized, Double-blind, Placebo-controlled, Study to investigate the Safety, Pharmacokinetics and Pharmacodynamics of CSL312 in Subjects with idiopathic Pulmonary Fibrosis. | Abgeschlossen |
| CADPT /  Novartis | CADPT09A12201 | II | Idiopathische Lungenfibrose | A participant- and investigator-blinded, randomized, placebo-controlled, multicenter, platform study to investigate efficacy, safety, and tolerability of various single treatments in participants with idiopathic pulmonary fibrosis | Aktiv |
| INSMED/  Insmed Incorporated | INS1009-211  (Treprostinil Palmitil) | II | PF-ILD | A Phase 2, Randomized, Double-Blind, Multicenter, Placebo Controlled Study to Evaluate the Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease. | Aktiv |
| FIBRONEER/  Boehringer-Ingelheim | BI 1015550 | III | Idiopathische Lungenfibrose / PF-ILD | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over 53´2 weeks in patients with IPF / Progressive Fibrosing Interstitial Lung Disease (PF-ILD). | Abgeschlossen |
| Modern IST 07 / Modern Bioscienses | MBS2320 | II | Idiopathische Lungenfibrose | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Investigate the Efficacy and Safety of MBS2320 in Patients With Idiopathic Pulmonary Fibrosis (IPF | In Vorbereitung |
| RIN-PF 303 /  United Therapeutics | Inhaled Trepostinil | III | Idiopathische Lungenfibrose | A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects with Idiopathic Pulmonary Fibrosis (TETON-2) | In Vorbereitung |
| Moonscape GB 44496 /  Genentech | Vixarelimab | II | Idiopathische Lungenfibrose / SSc-ILD | A two-cohort, Phase II, multicenter, randomized, double-blind, parallel-group, placebo-controlled study evaluating the efficacy and safety of vixarelimab compared with placebo in patients with idiopathic pulmonary fibrosis and in patients with systemic sclerosis–associated interstitial lung disease. | In Vorbereitung |
| Coral NAL 03-202 /  Trevi Therapeutics | Nalbuphine | IIb | Idipoathische Lungenfirbose | A Randomized, Double-Blind, Placebo-Controlled, Parallel, 4-Arm Dose Ranging Study of the Safety and Efficacy of Nalbuphine Extended-Release Tablets (NAL ER) for the Treatment of Cough in Idiopathic Pulmonary Fibrosis (IPF). | In Vorbereitung |
| Tefibeos /  Astra Zeneca | Tezepelumab | II | PF-ILD | A prospective two-armed, phase II clinical multicentre randomized, placebocontrolled (2:1), blinded with open-label extension | In Vorbereitung |
| IM027068 / IM0271015  Bristol Myers Squibb Company | BMS-986278 | III | Idiopathische Lungenfibrose / PPF | A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis /  A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis | In Vorbereitung |
| Beacon IPF /  Pliant | Bexotegrast | IIb | Idiopathische Lungenfibrose | A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF) | In Vorbereitung |
| **Alveolar Proteinose STUDIEN** | | | | | |
| IMPALA 2/  Savara | Molgramostin (GM-CSF inhalativ) | III | Alveolar Proteinose | A randomized, Double Blind, Placebo-controlled Clinical trial of once-daily inhaled Molgramostim nebulizer solution in adult subjects with autoimmune Alveolar-Proteinosis (aPAP). | Abgeschlossen |
| **Sarkoidose STUDIEN** | | | | | |
| CCMK389X2201/  Novartis | CMK389 | II | Sarkoidose | A subject and investigator blinded, randomized, placebocontrolled,  repeat-dose, multicenter study to investigate  efficacy, safety, and tolerability of CMK389 in patients with  chronic pulmonary sarcoidosis. | Abgeschlossen |
| Resolve Lung / Kinevant | Namilumab | II | Sarkoidose | A Randomized, Double-blind, Placebo-controlled Phase 2 Study with Open-label Extension to Assess the Efficacy and Safety of Namilumab in Subjects with Chronic Pulmonary Sarcoidosis | In Vorbereitung |
| ATYR1923-C-004 /  Atyr Pharma | Efzofitimod | III | Sarkoidose | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis. | In Vorbereitung |
| **Beobachtungsstudien / Registerstudien** | | | | | |
| Insight-ILD /  Boehringer-Ingelheim / GWD | INSIGHTS-ILD Register | NA | Idiopathische Lungenfibrose | INvestigating SIGnificant Health TrendS in Progressive Fibrosing Interstitial Lung Disease | Aktiv |